RTP Mobile Logo
Select Publications

Alderuccio JP, Sharman JP. ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma. Blood Rev 2022;[Online ahead of print]. Abstract

Bishop MR et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med 2022;386(7):629-39. Abstract

Budde LE et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study. J Clin Oncol 2022;40(5):481-91. Abstract

Caimi PF et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22(6):790-800. Abstract

Dickinson M et al. Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥2 prior therapies: Pivotal phase II expansion results. ASCO 2022;Abstract 7500.

Dickinson M et al. Glofitamab induces durable complete remissions and has favorable safety in patients with relapsed/refractory diffuse large B-cell lymphoma and ≥2 prior therapies: Pivotal phase II expansion results. EHA 2022;Abstract S220.

Dunleavy K. Double-high lymphoma: Optimizing therapy. Hematology Am Soc Hematol Educ Program 2021;(1):157-63. Abstract

Falchi L et al. First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update. ASCO 2022;Abstract 7523.

Jacobson C et al. Long-term (≥4- and ≥5-year) overall survival (OS) by 12- and 24-month event-free survival (EFS): An updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients (pts) with refractory large B-cell lymphoma (LBCL). ASH 2021;Abstract 1764.

Kamdar M et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 2022;399(10343):2294-308. Abstract

Karmali R. Relapsed disease: Off-the-shelf immunotherapies vs customized engineered products. Hematology Am Soc Hematol Educ Program 2021;2021(1):164-73. Abstract

Locke FL et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640-54. Abstract

Mehta-Shah N et al. Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study. Pan Pacific 2022.

Morschhauser F et al. Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX study. ASCO 2022;Abstract 7517.

Neelapu SS et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: The phase 2 ZUMA-12 trial. Nat Med 2022;28(4):735-42. Abstract

Neelapu SS et al. Interim analysis of ZUMA-12: A phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL). ASH 2020;Abstract 405.

Roschewski M et al. CAR T-cell therapy for large B-Cell lymphoma - Who, when, and how? N Engl J Med 2022;386(7):692-6. Abstract

Salles G et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21(7):978-88. Abstract

Sehgal A et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): An open-label, phase 2 study. Lancet Oncol 2022;23(8):1066-77. Abstract

Sehn LH et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: Survival update and new extension cohort data. Blood Adv 2022;6(2):533-43. Abstract

Simard J, Roschewski M. SOHO state of the art updates and next questions: Prophylaxis and management of secondary CNS lymphoma. Clin Lymphoma Myeloma Leuk 2022;[Online ahead of print]. Abstract

Sureda A et al. Clinical and patient-reported outcomes in a phase 3 study of axicabtagene ciloleucel (axi-cel) versus standard-of-care in elderly patients with relapsed/refractory large B-cell lymphoma (ZUMA-7). EHA 2022;Abstract S211.

Teras LR et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016;66(6):443-59. Abstract

Thieblemont C et al. Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). ASCO 2021;Abstract TPS7569.

Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract